Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2019

View Archived Issues

RHEB gene brain somatic mutation may cause focal cortical dysplasia type II

New antibody targets CAF-derived antigens in ovarian and pancreatic cancer

Phase I safety and immunogenicity data for GLS-5300 MERS vaccine

BI-2852 directly inhibits KRAS by binding to a pocket previously thought undruggable

Phase III results for fixed-dose combination of bempedoic acid plus ezetimibe

Children's Medical Center identifies new Rac-GTPase inhibitors

Array patents proto-oncogene tyrosine-protein kinase receptor Ret inhibitors

Brain diseases have shared superhighway vulnerabilities

PI3Kdelta inhibition may be useful in dementia

PCOS linked to interleukin-22 by way of microbiome

Ionis Pharmaceuticals describes oligonucleotides targeting human dynamin-2

New C5a-R antagonists identified at Idorsia Pharmaceuticals

GeneCentric enters second phase of academic-industry head and neck cancer partnership

Phase I study evaluates Fluzone and Flublok seasonal flu vaccines with two experimental adjuvants

AMPK-related kinases SIK1 and SIK3 identified as targets for non-small-cell lung cancer

Bristol-Myers Squibb initiates first-in-human study of BMS-986288

VenatoRx enrolling participants in phase III study of cefepime/VNRX-5133

Lysozyme inhibitors show promise for treating neuropathic pain

FDA clears IND application for first-in-human study of QR-1123

First patient enrolled in proof-of-concept trial of IMU-838 in primary sclerosing cholangitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...